AbCellera Biologics Inc.
$175,631,000.00 CAD
- Program
- SIF Stream 2 - Growth
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- April 11, 2020 – April 30, 2050
- Reference
- ic:033-2020-2021-Q1-512889
Published purpose
The project is in direct response to Canada's fight against COVID-19 and Canada's ability to respond to future pandemics. It will enable the rapid discovery of antibody therapies to treat and prevent COVID-19 and establish a Good Manufacturing Practice antibody production facility for Canada's long-term emergency preparedness.
In plain English AI-generated
This federal contribution supports AbCellera Biologics Inc. in developing antibody therapies for COVID-19 and building a Good Manufacturing Practice facility to strengthen Canada's pandemic preparedness.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.